8-K: Current report filing
Published on August 14, 2002
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
---------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
---------------------
Date of report: August 14, 2002
Access Pharmaceuticals, Inc.
----------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-9314 83-0221517
- ------------------------ ------------------------ -------------------
(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207
---------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (214) 905-5100
--------------
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
--------------------------------------------------------------------
(c) Exhibits.
---------
99.1 Certifications pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Item 9. Regulation FD Disclosure.
-------------------------
Attached as an exhibit to this Form 8-K are the certifications of Kerry P.
Gray, President and Chief Executive Officer of Access Pharmaceuticals,
Inc., and Stephen B. Thompson, Treasurer and Chief Financial Officer of
Access Pharmaceuticals, Inc., made solely for the purpose of satisfying the
requirements of Section 906 of the Sarbanes-Oxley Act of 2002.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ACCESS PHARMACEUTICALS, INC.
Dated: August 14, 2002 By: /s/ Kerry P. Gray
----------------------------
Name: Kerry P. Gray
Title: President and Chief Executive Officer